Clinical Trial Update: A Phase 1 Trial of OPB-111077 in Combination With Bendamustine and Rituximab in Patients With r/r DLBCL [Phase 1]

View source ↗

Summary

This document summarizes a completed Phase 1 trial evaluating OPB-111077 in combination with bendamustine and rituximab for relapsed or refractory diffuse large…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• Bendamustine (Bendamustine)
• OPB-111077
• Rituximab (rituximab)

Snippet

Sponsor: Otsuka Pharmaceutical Co., Ltd. | Conditions: Relapsed or Refractory Diffuse Large B-cell Lymphoma | Phase 1 | Status: COMPLETED